# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $152 to $...
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered...